Shenzhen Kangtai Biological Products Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shenzhen Kangtai Biological Products Co., Ltd. was established in 1992 and focuses on the research and development, production, and sales of human vaccines. In February 2017, it was listed on the Shenzhen Stock Exchange ChiNext (stock code: 300601) and became the first vaccine enterprise to be listed in South China. The company is headquartered in Shenzhen and has five R&D industry bases in Beijing and Shenzhen, including the headquarters base in Nanshan District, the research and production base for new vaccines in Nanshan District, Kangtai Biological Park in Guangming District, Minhai Biological Vaccine Industry Base, and Minhai Biological New Vaccine International Industry Base. The production scale ranks among the top in the domestic vaccine industry, and the marketing and distribution network covers 31 provinces (autonomous regions, municipalities directly under the central government) in China. Since its establishment 30 years ago, Kangtai Biology has developed into a high-tech enterprise with complete research and development varieties, rich product lines, and obvious technological advantages. It has the R&D and production capacity of viral vaccines, bacterial vaccines, genetic engineering vaccines, conjugated vaccines, multi linked multi valent vaccines, etc. Six products have been listed and approved for drug registration, of which 60 microgram hepatitis B vaccine is the world's first, The cellless diphtheria pertussis type B influenza hemophilus combination vaccine (quadruple vaccine) is exclusive in China. As for hepatitis B vaccine alone, Kangtai Biology has produced and sold more than 1.2 billion doses, helped more than 400 million people to avoid the invasion of hepatitis B virus, and reduced public health expenditure for the country by more than 160 billion yuan, which has important economic and social value. The company has over 50 patents and over 30 varieties under research, covering basically key global vaccine varieties. In terms of international cooperation, the company has conducted extensive technical cooperation with internationally renowned biopharmaceutical companies such as Merck in the United States, INTRAVACC in the Netherlands, Sanofi Pasteur in France, and AstraZeneca in the UK, bringing the world's leading biological vaccine technology to China and innovating on the basis of digestion and absorption, laying a solid foundation for China's vaccine to enter the world stage and participate in international competition. At present, COVID-19, Kangtai Biology is duty bound to shoulder the burden of anti epidemic, and the independently developed COVID-19 inactivated vaccine was approved for emergency use in May 2021; The internationally introduced adenovirus vector COVID-19 vaccine is actively promoting domestic clinical registration, production and commercialization; He has also made fruitful exploration and practice in the research and development of COVID-19 mutant vaccine and mRNA vaccine technology. Facing the future, Kangtai Biotechnology will continue to take "creating better vaccines for the benefit of human health" as its responsibility, with quality and safety as the foundation, research and development innovation as the driving force, and strive to build a domestic first-class and internationally renowned large-scale biopharmaceutical multinational company, and make greater contributions to safeguarding national life and health!. |
| Headquarter | Shenzhen |
| Establish Date | 9/8/1992 |
| Listed Code | 300601.SZ |
| Listed Date | 2/7/2017 |
| Chairman | Du Weimin. |
| CEO | Miao Xiang. |
| Website | www.biokangtai.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
